Search results
Results from the WOW.Com Content Network
Central Nervous System Prophylaxis, or CNS prophylaxis, is a type of chemotherapy for patients at risk of cancer metastasis into the central nervous system (CNS). [1] Prophylaxis originated from the Greek word “phulaxis”, meaning the act of guarding. [ 2 ]
Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...
The risk is much lower than that with nilutamide (which has an incidence rate of 0.5–2% of patients). [184]: 81 [180] [185] In a large cohort of prostate cancer patients, the incidence of interstitial pneumonitis with NSAAs was 0.77% for nilutamide, 0.04% (4 per 10,000) for flutamide, and 0.01% (1 per 10,000) for bicalutamide. [3]
Bicalutamide, sold under the brand name Casodex among others, is an antiandrogen medication that is primarily used to treat prostate cancer. [10] It is typically used together with a gonadotropin-releasing hormone (GnRH) analogue or surgical removal of the testicles to treat metastatic prostate cancer (mPC).
A central nervous system tumor (CNS tumor) is an abnormal growth of cells from the tissues of the brain or spinal cord. [1] CNS tumor is a generic term encompassing over 120 distinct tumor types. [2] Common symptoms of CNS tumors include vomiting, headache, changes in vision, nausea, and seizures. [3]
Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. [2] [9] It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer (mCRPC), [2] nonmetastatic castration-resistant prostate cancer, [2] and metastatic castration-sensitive prostate ...
CNS metastasis is the spread and proliferation of cancer cells from their original tumour to form secondary tumours in portions of the central nervous system. [ 1 ] The process of tumour cells invading distant tissue is complex and obscure, but modern technology has permitted an enhanced detection of metastasis .
ARIAD’s most prominent drug discoveries include Iclusig, designed for patients with all forms of Philadelphia chromosome-positive [Ph+] chronic myeloid leukemia (CML) or Ph+ acute lymphoblastic leukemia (ALL) who are resistant to or unable to tolerate other tyrosine kinase inhibitors, and brigatinib, a lung cancer drug which has completed its ...